A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients

A Dakin, R Borrow, PD Arkwright - Expert Review of Vaccines, 2023 - Taylor & Francis
Introduction Hexaxim is a hexavalent vaccine approved as primary and booster vaccination
in infants 6 weeks and older, protecting against diphtheria, tetanus, pertussis, poliomyelitis …
被引用次数：6 相关文章

A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients

A Dakin, R Borrow… - Expert Review of …, 2023 - researchportal.ukhsa.gov.uk
Introduction: Hexaxim is a hexavalent vaccine approved as primary and booster vaccination
in infants 6 weeks and older, protecting against diphtheria, tetanus, pertussis, poliomyelitis …

A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients.

A Dakin, R Borrow, PD Arkwright - Expert Review of Vaccines, 2022 - europepmc.org
Hexaxim is a hexavalent vaccine approved as primary and booster vaccination in infants 6
weeks and older, protecting against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B …

A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients

A Dakin, R Borrow… - Expert Reviews of …, 2022 - research.manchester.ac.uk
Introduction: Hexaxim is a hexavalent vaccine approved in 2013 for use the EU as primary
and booster vaccination in infants 6 weeks and older, protecting against diphtheria, tetanus …

A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients

A Dakin, R Borrow… - Expert review of …, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction Hexaxim is a hexavalent vaccine approved as primary and booster vaccination
in infants 6 weeks and older, protecting against diphtheria, tetanus, pertussis, poliomyelitis …